Kidney Stone Drug Pipeline — PatSnap Eureka
Kidney Stone Drug Pipeline: URAT1 Inhibitors, Oxalate Enzymes & Gene Therapy
Nephrolithiasis affects approximately 12% of the global population with a first-5-year recurrence rate exceeding 50%. Explore the emerging pipeline of mechanistically targeted therapies — from XOR inhibitors and engineered uricases to siRNA platforms and AIM/CD5L biologics.
A Multifactorial Metabolic Disorder with Multiple Druggable Nodes
Nephrolithiasis is a multifactorial chronic metabolic disorder driven by urinary supersaturation, crystal nucleation, growth, aggregation, and retention within the renal tubular environment. Calcium oxalate (CaOx) stones are the predominant form, accounting for more than 75% of cases, with uric acid (UA) stones representing a secondary but clinically significant subtype.
At the molecular level, several intersecting target clusters have been identified. Renal tubular epithelial cell injury driven by CaOx monohydrate (COM) crystals involves upregulation of NADPH oxidase isoforms (NOX2, NOX4), reactive oxygen species (ROS) generation, activation of NF-κB, and downstream inflammatory cytokine release including IL-1β, IL-6, and TNF-α.
For uric acid stone disease, patent landscape analysis reveals that URAT1 (encoded by SLC22A12) is the dominant renal proximal tubule urate reabsorber. Dysregulation of xanthine oxidoreductase (XOD) and renal urate transporters is identified as a primary cause of hyperuricemia and uric acid nephrolithiasis. The role of Oxalobacter formigenes — an intestinal oxalate-degrading bacterium — in regulating systemic oxalate load positions gut microbiome correction as an additional therapeutic target for oxalate stone formers.
The World Intellectual Property Organization patent database and academic literature accessed via PatSnap Eureka reveal a pipeline diversifying rapidly beyond classical surgical lithotripsy and potassium citrate therapy toward precision molecular interventions.
Pipeline Data: Targets, Modalities & Evidence Signals
Key data points extracted from patent filings and academic literature via PatSnap Eureka — all values traceable to source records.
Molecular Target Evidence Landscape
XOR/XOD leads with 3 patents plus clinical evidence; URAT1, NOX4, and ERK1/2 have strong preclinical signals from multiple independent research groups.
Kidney Stone Composition: Clinical Prevalence
Calcium oxalate stones account for more than 75% of all kidney stone cases; uric acid stones are a secondary but clinically significant subtype driving the uricosuric pipeline.
Seven Mechanistic Approaches in the Kidney Stone Pipeline
From clinically approved XOR inhibitors to preclinical gene therapy, the pipeline spans diverse mechanisms addressing uric acid production, oxalate crystal formation, transporter biology, and genetic disease drivers.
Xanthine Oxidoreductase (XOR) Inhibitors
Three patent filings from TAP Pharmaceutical Products, Inc. and inventor Nancy Joseph-Ridge describe methods for treating nephrolithiasis with XOR-inhibiting compounds, with febuxostat (2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid) as the named clinical agent. XOR catalyzes the final two steps of purine catabolism; inhibition reduces serum and urinary urate, preventing uric acid crystalluria. Clinical evidence includes complete crystal clearance at 80 mg/day febuxostat post-transplant (Jichi Medical University, 2017).
Clinical / ApprovedEngineered Uricase & Oxalate-Degrading Enzymes
ALLN-346 is an orally administered, proteolytically stabilized urate oxidase engineered for intestinal urate degradation — bypassing the IV-only limitation of rasburicase. In uricase-knockout mice with uric acid obstructive nephropathy, ALLN-346 significantly reduced plasma urate, urinary urate, and uric acid crystal burden. Clinical precedent is established: IV rasburicase achieved complete bilateral stone dissolution in a patient with refractory hyperuricemia-associated nephrolithiasis (Manchester Royal Infirmary, 2016).
Preclinical (ALLN-346)URAT1 & Urate Transporter-Targeted Strategies
URAT1 (SLC22A12) is identified as the dominant urate reabsorber in the renal proximal tubule. Uricosuric inhibitors of URAT1 historically carry an associated risk of increasing urinary urate crystallization, motivating development of selective modulators. The CPE study (Hunan Academy of Chinese Medicine, 2023) demonstrates reversal of upregulated renal URAT1 expression alongside improved OAT1-mediated urate secretion — a dual-transporter correction mechanism. No retrieved patent specifically claims a selective URAT1 inhibitor for the nephrolithiasis indication.
PreclinicalOligonucleotide & Gene Therapy Approaches
Quark Pharmaceuticals, Inc. (EP, 2020) discloses oligonucleotide compounds targeting human p53 and CASP2 gene expression to prevent or delay CKD onset, including kidney disease arising from recurrent renal insults. The approach uses siRNA/antisense oligonucleotides to suppress apoptotic signaling in tubular cells, reducing cumulative injury from repeated stone events. INSERM (EP, 2018) separately targets periostin — an upregulated fibrosis marker in tubulo-interstitial compartments — as a gene-expression target for disease-modifying intervention.
Early TranslationalUric Acid Crystallization Inhibitors + pH Modifiers
The Universitat de les Illes Balears (EP, active, 2019) claims a sequential or simultaneous combination of urinary basifying agents (citrate, bicarbonate, polyhydroxycarboxylic acids) with uric acid crystallization inhibitors to maintain urinary pH above the supersaturation threshold. This directly addresses the pH-solubility relationship of uric acid (pKa ~5.35; solubility dramatically increases above pH 6.0), extending the rationale of potassium citrate therapy with more targeted anti-crystallization pharmacology.
Active Patent · Combination PharmacotherapyPhytic Acid / Magnesium / Polyphenol Compositions
A second active EP patent from Universitat de les Illes Balears (2019) claims synergistic inhibition of calcium salt crystallization through phytate (a known calcium chelator), magnesium (competitive inhibitor of oxalate-calcium binding), and polyphenol-mediated reduction of oxidative stress and papillary injury. A Phase II randomized, prospective, single-blind study (n=155; 120 treatment, 35 placebo; Nicaragua, 2021) evaluating phytotherapy for calcium oxalate and struvite stones is the only retrieved result explicitly labeled as a Phase II clinical trial in this dataset.
Phase II Clinical TrialWho Is Filing Patents in Kidney Stone Drug Development?
Innovation activity in this dataset is distributed across commercial pharmaceutical companies, academic medical centers, and governmental research institutions.
| Assignee / Institution | Country / Region | Modality | Key Compound / Target | Stage |
|---|---|---|---|---|
| TAP Pharmaceutical Products, Inc. | US / CA | XOR Inhibitor | Febuxostat | Clinical |
| Joseph-Ridge, Nancy | US | XOR Inhibitor | Febuxostat (nephrolithiasis method) | Clinical |
| Universitat de les Illes Balears | EP (Active) | Combination Pharmacotherapy | Citrate/bicarbonate + crystallization inhibitor; phytate/Mg/polyphenol | Active Patent |
| Quark Pharmaceuticals, Inc. | EP | Gene Therapy / siRNA | p53 / CASP2 oligonucleotides | Early Translational |
| INSERM | EP | Oligonucleotide / Anti-fibrotic | Periostin targeting | Early Translational |
| Shire International Licensing B.V. | PH | GI Oxalate Binder | Lanthanum compounds (dietary oxalate binding) | Preclinical |
Identify emerging assignees before they dominate the IP landscape
PatSnap Eureka tracks real-time patent filings across 120+ countries for the full nephrolithiasis pipeline.
IP White Spaces & Emerging Opportunities in Nephrolithiasis
Key strategic signals derived from patent and literature analysis — all traceable to source records retrieved via PatSnap Eureka.
URAT1 Inhibitor Indication Gap
Retrieved results establish the mechanistic rationale for URAT1 as primary urate reabsorber and identify reversal of URAT1 upregulation as pharmacologically feasible, yet no retrieved patent specifically claims a selective URAT1 inhibitor for the nephrolithiasis indication — representing an IP white space opportunity distinct from the gout indication.
Oral Engineered Uricase: Disruptive Platform
Preclinical data for ALLN-346 demonstrate efficacy in a relevant obstructive nephropathy model. The combination of proteolytic stability engineering and intestinal delivery overcomes the IV administration constraint of rasburicase, enabling chronic preventive use in recurrent uric acid nephrolithiasis.
NOX4-ERK1/2-NLRP3 Multi-Target Opportunity
Retrieved results from multiple independent groups converge on this cascade as central to oxalate and urate crystal-induced tubular injury and fibrosis. Small-molecule inhibitors at any node — NOX4 inhibitors such as GKT137831, ERK1/2 inhibitors, IL-1β/NLRP3 inhibitors — are mechanistically supported for combination with stone-prevention agents to address end-organ damage in recurrent formers.
Gene Therapy as Combination Partner
The Quark Pharmaceuticals patent targets p53/CASP2-mediated apoptosis in the context of recurrent renal insults. For drug developers, this positions siRNA renal delivery platforms as potential combination partners with metabolic stone therapies — XOR inhibitors, URAT1 inhibitors — for patients with CKD driven by high stone recurrence rates.
From Preclinical Proof-of-Concept to Clinical Evidence
The pipeline contains several distinct clinical and translational signals. The case report from Jichi Medical University (2017) documents successful prevention of recurrent crystal nephropathy with febuxostat 80 mg/day in a kidney transplant recipient — representing direct clinical evidence for XOR inhibition in stone-related nephropathy, specifically 2,8-dihydroxyadenine (DHA) nephropathy.
A network meta-analysis from Sichuan University (2021) synthesizes RCT data comparing urate-lowering therapy (ULT) drugs for renal functional outcomes in CKD with hyperuricemia — providing clinical trial-level evidence for this drug class. This is supported by life sciences patent intelligence showing sustained commercial investment in XOR-targeting approaches.
Importantly, no retrieved results include Phase III trial data, regulatory submissions, or approved indications for URAT1 inhibitors, gene therapies, or engineered oxalate-degrading enzymes specifically for nephrolithiasis. The only retrieved result explicitly labeled as a Phase II clinical trial is the Renalof® phytotherapy study (Nicaragua, 2021; n=155; 120 treatment, 35 placebo) for calcium oxalate and struvite stones.
Genetic polymorphism data from a meta-analysis of 14 studies (Universitas Indonesia, 2021) on VDR and urokinase (ApaL1) polymorphisms provides clinical genetic evidence relevant to patient stratification for recurrent stone risk — a foundation for precision medicine approaches. For deeper analysis of the clinical trial landscape, the ClinicalTrials.gov registry and PatSnap customer case studies illustrate how R&D teams navigate these evidence gaps.
Multi-Mechanism Strategies Emerging from the Pipeline
Retrieved results signal several combination and emerging strategic directions where independent drug programs may converge into multi-target regimens.
Kidney Stone Combination Strategy Framework
Six emerging combination directions identified from patent and literature signals — from dual XOR+URAT1 targeting to AIM/CD5L + anti-fibrotic multi-phase strategies.
Kidney Stone Drug Pipeline — key questions answered
Xanthine oxidoreductase (XOR/XOD) is the single most patent-active target in this dataset. Three issued US and CA patents from TAP Pharmaceutical Products, Inc. and inventor Nancy Joseph-Ridge explicitly claim XOR inhibitors for the nephrolithiasis indication, with febuxostat as the named clinical agent.
URAT1 (encoded by SLC22A12) is the dominant renal proximal tubule urate reabsorber. Retrieved results establish the mechanistic rationale — URAT1 as primary urate reabsorber and its upregulation in hyperuricemic nephropathy — and identify reversal of URAT1 upregulation as pharmacologically feasible. No retrieved patent specifically claims a selective URAT1 inhibitor for the nephrolithiasis indication, representing an IP white space opportunity distinct from the gout indication.
ALLN-346 is an orally administered, proteolytically stabilized urate oxidase engineered for intestinal urate degradation — bypassing the IV-only limitation of rasburicase. In uricase-knockout mice with uric acid obstructive nephropathy, ALLN-346 significantly reduced plasma urate, urinary urate, and uric acid crystal burden. Clinical precedent for enzymatic urate degradation is established with IV rasburicase, which demonstrated complete bilateral stone dissolution in a patient with refractory hyperuricemia-associated nephrolithiasis.
NOX4 (NADPH Oxidase 4) is identified as a key mediator of CaOx crystal-induced ROS generation in renal tubular cells. Both pharmacological inhibition (GKT137831, a NOX4-selective inhibitor) and natural compound-mediated NOX4 suppression reduce tubular injury markers and crystal deposition in vivo. The NOX4-ERK1/2-NLRP3 inflammation axis is described as a multi-target opportunity, with small-molecule inhibitors at any node mechanistically supported for combination with stone-prevention agents.
Yes. Quark Pharmaceuticals, Inc. holds an EP patent disclosing oligonucleotide compounds targeting human p53 and CASP2 gene expression to prevent or delay CKD onset, including kidney disease arising from recurrent renal insults. The approach uses siRNA/antisense oligonucleotides to suppress apoptotic signaling in tubular cells, reducing cumulative injury from repeated stone events. Development stage is preclinical/early translational.
Nephrolithiasis affects approximately 12% of the global population and carries a first-5-year recurrence rate exceeding 50%. The therapeutic landscape is undergoing diversification beyond classical approaches — surgical lithotripsy and potassium citrate — toward mechanistically targeted interventions addressing uric acid metabolism, oxalate crystal formation, transporter biology, and genetic underpinnings of recurrent disease.
Still have questions? Let PatSnap Eureka search the patent and literature database for you.
Ask PatSnap Eureka About Kidney Stone DrugsAccelerate Your Kidney Stone Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map pipeline gaps, identify IP white spaces, and track emerging modalities in nephrolithiasis and beyond.
References
- NADPH Oxidase as a Therapeutic Target for Oxalate Induced Injury in Kidneys — University of Florida College of Medicine, 2013
- New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds — Shandong Qingyujiangxing Biotechnology Co., Ltd., 2022
- Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics — University of California San Diego, 2006
- Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice — Hospital Universitario de Canarias, Universidad La Laguna & CIBERER, 2020
- Dissolution of extensive urolithiasis: extending the utility of rasburicase can avoid the need for surgical intervention and renal replacement therapy — Manchester Royal Infirmary, 2016
- Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease — University of Bristol, 2021
- State of the gut microbiota in oxalate nephrolithiasis — RUDN University, 2022
- Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1 — Tokyo Women's Medical University, 2022
- Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation — Jichi Medical University, 2017
- Efficacy of Obcordata A from Aspidopterys obcordata on Kidney Stones by Inhibiting NOX4 Expression, 2019
- Cyclocarya paliurus leaves alleviate hyperuricemic nephropathy via modulation of purine metabolism, antiinflammation, and antifibrosis — Hunan Academy of Chinese Medicine, 2023
- Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy — Fudan University, 2017
- Telmisartan Attenuates Uric Acid-Induced Epithelial-Mesenchymal Transition — Wuhan University, 2019
- Hydroxycitric acid inhibits kidney stone through crystallization regulation and reduction of hyperoxalate-induced lipotoxicity — Guangzhou Medical University, 2023
- Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia — Sichuan University, 2021
- Effectiveness of Renalof® in the Elimination of Kidney Stones under 10 mm — Phase II RCT, Nicaragua, 2021
- Genetic polymorphisms as prognostic factors for recurrent kidney stones — Universitas Indonesia, 2021
- World Intellectual Property Organization (WIPO) — Patent Database
- National Institutes of Health (NIH) — NADPH Oxidase Research Resources
- ClinicalTrials.gov — Nephrolithiasis Clinical Trial Registry
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.